← All countries · Europe
83%
MCV1
2025 · WHO/UNICEF estimate
85%
DTP3
2025 · WHO/UNICEF estimate
85%
IPV complete
2025 · WHO/UNICEF estimate
85%
HepB3
2025 · WHO/UNICEF estimate
11
Measles cases
2025 reported
141
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 88%2025 · WHO/UNICEF estimate | 87.6% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 86%2025 · WHO/UNICEF estimate | 86.1% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 85%2025 · WHO/UNICEF estimate | 85.5% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 86%2025 · WHO/UNICEF estimate | 86.1% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 85%2025 · WHO/UNICEF estimate | 85.5% | C · weak | |
| MCV1First dose of measles-containing vaccine | 83%2025 · WHO/UNICEF estimate | 82.7% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 75%2025 · WHO/UNICEF estimate | 74.7% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 83%2025 · WHO/UNICEF estimate | 82.7% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 85%2025 · WHO/UNICEF estimate | 85.5% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 96.3%2005 · Administrative (country-reported) | 96.3% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 85%2025 · WHO/UNICEF estimate | 85.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | no data |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | —% · Administrative (country-reported) | — | too few points | no data |
| RotaCRotavirus vaccine, complete series | 80%2025 · WHO/UNICEF estimate | 80.2% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 65%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 65%2025 · WHO/UNICEF estimate | — | C · weak | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 55%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 112025 | 8.2per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 22025 | 1.5per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 1412025 | 104.9per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 52025 | 3.7per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (44 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | D1-D5 | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | Risk group(s) | Children with contrindication to pertussis component | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M3 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4.5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M6 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | Y2 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y6-Y7 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | Birth dose for risk group newborns (newborn of HIV-positive or untested mother), and vaccination for children with contraindication to pertussis component, children unvaccinated/partially vaccinated against HepB |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | Children with contrindication to pertussis component | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Catch-up children | main group 12-14yo girls and boys; catch-up group 15-18yo girls and boys (since feb. 2024). | |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12-Y14 | HPV administered to females and males | main group 12-14yo girls and boys; catch-up group 15-18yo girls and boys (since feb. 2024). |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons >=60 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M3 | Risk group(s) | Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated |
| IPVIPV (Inactivated polio vaccine) | 2 | M4.5 | Risk group(s) | Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | Risk group(s) | Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated |
| IPVIPV (Inactivated polio vaccine) | 4 | Y2 | Risk group(s) | Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated |
| IPVIPV (Inactivated polio vaccine) | 5 | Y6-Y7 | Risk group(s) | Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Y1 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Risk group(s) | Close contacts of measles cases | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y13 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M3 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M4.5 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Adults | Older adults | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnant women | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Risk group(s) | People with chronic conditions | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y15-Y16 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y25 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Risk group(s) | children >13 years with incomplete vaccination schedule, post-trauma vaccination | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +Y10 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +Y10 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y10 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y10 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | +Y10 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y15-Y16 | General/routine | and for children >13 years with incomplete vaccination schedule |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.